In addition, the activity of combined trastuzumab and pertuzumab was also low in a cohort of endometrial cancer in the phase II MyPathway basket trial in HER2-positive tumors, with a 4.3% ORR [118,119]. The gene discussed is ERBB2; the disease is endometrial cancer.